DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.
Read More…
Industry, Sector and Symbol
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
Phone720-631-2100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$11.40 billion
Profitability
Miscellaneous
Employees77,700
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Davita (NYSE:DVA) Frequently Asked Questions
What is Davita's stock symbol?
Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How were Davita's earnings last quarter?
Davita Inc (NYSE:DVA) posted its quarterly earnings data on Thursday, August, 1st. The company reported $1.22 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.10 by $0.12. The business earned $2.84 billion during the quarter, compared to the consensus estimate of $2.86 billion. Davita had a return on equity of 14.67% and a net margin of 1.21%. Davita's quarterly revenue was down 1.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.05 earnings per share. View Davita's Earnings History.
When is Davita's next earnings date?
What price target have analysts set for DVA?
8 brokers have issued 1 year price targets for Davita's stock. Their predictions range from $60.00 to $70.00. On average, they expect Davita's stock price to reach $65.35 in the next twelve months. This suggests a possible upside of 15.8% from the stock's current price. View Analyst Price Targets for Davita.
What is the consensus analysts' recommendation for Davita?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Davita.
Has Davita been receiving favorable news coverage?
News stories about DVA stock have been trending negative on Sunday, InfoTrie reports. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Davita earned a news sentiment score of -2.6 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the next several days. View News Stories for Davita.
Are investors shorting Davita?
Davita saw a decline in short interest during the month of September. As of September 30th, there was short interest totalling 10,930,000 shares, a decline of 16.8% from the August 30th total of 13,130,000 shares. Based on an average daily trading volume, of 3,100,000 shares, the short-interest ratio is currently 3.5 days. Currently, 7.1% of the shares of the stock are short sold. View Davita's Current Options Chain.
Who are some of Davita's key competitors?
What other stocks do shareholders of Davita own?
Who are Davita's key executives?
Davita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 63)
- Mr. Joel Ackerman, Chief Financial Officer (Age 54)
- Mr. James K. Hilger, Chief Accounting Officer (Age 57)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 51)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 48)
Who are Davita's major shareholders?
Davita's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Crossmark Global Holdings Inc. (0.02%), State of Alaska Department of Revenue (0.01%), Rothschild Investment Corp IL (0.01%), Pacer Advisors Inc. (0.01%), Stonebridge Capital Management Inc. (0.01%) and Lau Associates LLC (0.01%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.
Which major investors are selling Davita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, Lau Associates LLC, Stonebridge Capital Management Inc., Crossmark Global Holdings Inc. and Pacer Advisors Inc.. View Insider Buying and Selling for Davita.
Which major investors are buying Davita stock?
DVA stock was acquired by a variety of institutional investors in the last quarter, including Rothschild Investment Corp IL and North Star Investment Management Corp.. View Insider Buying and Selling for Davita.
How do I buy shares of Davita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Davita's stock price today?
One share of DVA stock can currently be purchased for approximately $56.44.
How big of a company is Davita?
Davita has a market capitalization of $9.05 billion and generates $11.40 billion in revenue each year. The company earns $159.39 million in net income (profit) each year or $3.57 on an earnings per share basis. Davita employs 77,700 workers across the globe.View Additional Information About Davita.
What is Davita's official website?
How can I contact Davita?
Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 720-631-2100 or via email at [email protected]
MarketBeat Community Rating for Davita (NYSE DVA)
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
